Sensodyne alternatives in the UK: a guide by active ingredient, not by brand loyalty.

There are five desensitising actives on the UK sensitivity shelf, and the alternatives worth your money are the ones carrying an active you have not already had: potassium salts, stannous fluoride, arginine with calcium carbonate, bioactive glass, and hydroxyapatite. Turn the tube over, read which of the five it carries, and shop by mechanism instead of by name. S3 Sensitivity Science™'s ingredient list carries potassium nitrate, hydroxyapatite and a fluoride salt; the closest competitor on the same shelf, Spotlight Sensitivity + Rebuilding Pro, carries potassium citrate, hydroxyapatite and sodium fluoride.

What was checked19 peer-reviewed studies, product information as published by each brand, the Oral Health Foundation and the NHS

Which active are you actually replacing?

Whichever one is printed on the tube in your bathroom, and the market leader sells three of the five. Its range decodes into calcium sodium phosphosilicate in the repair variants, stannous fluoride in the gum and rapid variants, and potassium nitrate in the daily and enamel variants; a companion page decodes the range variant by variant. This page compares ingredients and stated actions only, not clinical performance, based on what each brand states about its own formula. Prices and formulations may change; always check the pack.

Naming the active matters because the three do different jobs. Potassium calms the nerve; nano-hydroxyapatite works inside the tubule; biomimetic hydroxyapatite works on the surface; each does a job the others cannot. Stannous fluoride, arginine and bioactive glass all work at the tubule mouth. So a reader leaving a potassium tube for another potassium tube has changed the packaging, and a reader leaving a bioactive-glass tube for a stannous tube has swapped one occluder for another. The switch that changes something is the one that adds the half you never had.

What are the five actives on the UK sensitivity shelf?

Potassium salts, stannous fluoride, arginine with calcium carbonate, bioactive glass and its relatives, and hydroxyapatite. Every row below is a product whose ingredient list was read from a brand or retailer page in September 2026, with the level as the holder declares it, the fluoride salt and its parts per million, whether water appears in the list, and the price on the day converted to a common 75 ml tube so the rows can be compared. Every row, with its source URL and the date it was read, sits in the category review.

Three reading notes, because the table hides them. Only six of the twenty-one rows publish the level of the active they are sold for, so "not declared" is the commonest entry in that column and it means the holder did not print the number, never that the number is low. The water column is chemistry rather than trivia: a formula built on bioactive glass has to be water-free, which is why the glass rows list no aqua and the potassium rows do. And several hydroxyapatite pastes sold to British readers online are not established on a British shelf at all, so they are left out of the table rather than implied to be a trip to Boots: a Japanese nano-hydroxyapatite paste on Amazon UK and importers, a German paste whose shop redirects to a European site, and three United States brands that price in dollars. Four more products publish no ingredient list in their page text at all, so they are absent from the table rather than guessed at.

What does the pooled evidence say for each, and how sure is it?

Less than the front of any pack says, and the three network meta-analyses disagree with each other. Take the newest first. Published in 2026 and pooling 93 randomised trials with 9,548 participants, it is useful here because it prints a confidence grade beside every estimate instead of a league position, and it is a systematic review with a network meta-analysis behind it: against a benchmark fluoride paste at two weeks on the cold-air score, stannous fluoride gave a mean difference of −0.85 from ten trials with high confidence, nano-hydroxyapatite −0.96 from two trials with moderate confidence, arginine −0.78 from seven trials with low confidence, potassium with or without fluoride −0.42 from one trial with low confidence, and bioactive glass −0.36 from three trials with low confidence and an interval running to 0.01¹. Their recommendation, in their own words, is that stannous fluoride and arginine be treated as first-line self-care, and that anyone picking between the two go by what a patient can tolerate, prefer and actually buy¹.

Read the two earlier networks and the order moves. The 2020 network meta-analysis of 125 randomised trials in 12,541 patients put calcium sodium phosphosilicate first across the tactile, cold and air stimuli, with potassium ahead of fluoride paste on the tactile stimulus at a standardised mean difference of 1.23³. The 2019 network meta-analysis of 30 randomised trials gave nano-hydroxyapatite the highest probability of being the most effective at two and four weeks, and arginine the highest at eight, while finding no significant difference between bioactive glass, potassium and strontium, and none between potassium and placebo⁴. Three networks, three orders. That is what a field looks like when its studies are small, its outcomes are subjective and most of its comparisons are indirect¹³⁴.

Active by active, the picture is this. Potassium is at once the most-tested and the least certain of the five. Pooling six randomised trials, the Cochrane systematic review of 2006 put the air-blast standardised mean difference at −1.25 by six to eight weeks, found nothing significant in what the patients themselves said, and closed by calling the evidence unclear⁵. A 2018 systematic review and meta-analysis of 53 randomised trials in 4,796 patients put potassium above a no-active control, in its low-quality band⁶. Across nine randomised trials pooled in 2017, the potassium nitrate pastes moved in the right direction without ever crossing the significance line, while strontium acetate and arginine did cross it⁷.

Of the five, stannous fluoride has the best-evidenced record in the pooled analyses, and it is not on S3's list¹. Besides its high-confidence row in the newest network, a meta-analysis of 14 randomised trials in 1,287 participants drawn from the manufacturer's own archive, by authors who include employees of that manufacturer, reported a 57% cold-air and 142% tactile benefit against negative controls and a 22% advantage over potassium or arginine controls⁸. In an industry-funded double-blind trial of 120 adults, potassium nitrate had not separated from the control on the probe test at day three, and by week eight the three actives tested had improved cold-air scores by 57%, 47% and 44% against control, with no significant difference between them⁹. Between the two occluding chemistries there is nothing to choose: a systematic review and meta-analysis of five studies found no significant difference between arginine and bioactive glass out to four weeks, at very low certainty¹⁰. An industry-funded examiner-blind trial of 215 adults put a 5% bioactive-glass paste ahead of a plain fluoride paste from day three, with the gap still widening at day 56¹¹.

One finding changes how every row above should be read. In a six-month single-blind randomised placebo-controlled crossover trial in 35 patients of a professionally applied calcium-phosphate paste, the water placebo on its own cut air-blast pain by 20% immediately and by 36% at six months¹². That was not a toothpaste and it does not transfer to one, but the 2019 network meta-analysis measured a significant placebo effect across its trials too⁴: a fortnight of feeling more comfortable after a new tube is not, by itself, evidence that the active did the work.

Timing is the one thing the pooled work agrees on. A 2019 systematic review of 74 randomised trials in 5,366 patients grouped treatments by when their effect reached significance and found only in-office treatments acting inside seven days, with stannous fluoride and hydroxyapatite reaching it in the medium term and potassium nitrate, arginine and hydroxyapatite in the long term¹³. Nothing on this shelf is a weekend fix.

Finally, a contrast the shelf never shows you. A 2022 systematic review counted 368 toothpaste formulations across 138 trials and found potassium compounds in 68 of them and hydroxyapatite in nine². The active with the thinnest record in the trial literature sits at the top of the price range, and the one with the thickest sits at the bottom.

Which alternatives keep fluoride, and which ask you to give it up?

Of the recorded hydroxyapatite rows, most declare no fluoride at all, and three competitors pair hydroxyapatite with a fluoride salt. One of those three also carries a potassium salt: Spotlight Sensitivity + Rebuilding Pro is a water-based tube with potassium citrate, hydroxyapatite and 1450 ppm sodium fluoride, and the distance between it and S3's own list is one word in the potassium salt: citrate, not nitrate. That is worth saying plainly on a page like this one, because a reader who checks will find it in a minute.

What a fluoride-free paste costs you is decay protection, and the honest reading of the evidence is that it is a real cost with an uncertain size. A 2025 systematic review and meta-analysis of four randomised trials in young people found fluoride-free hydroxyapatite and fluoride toothpastes statistically indistinguishable on caries outcomes, with a pooled risk ratio of 0.98¹⁴. A 2024 systematic review and meta-analysis whose authors include two scientists employed by a hydroxyapatite toothpaste manufacturer concluded that hydroxyapatite works as an anti-caries active without fluoride, and reported no pooled effect size¹⁵. Against both, a 2022 systematic review of ten clinical and in situ studies found no conclusive evidence for nano-hydroxyapatite in caries prevention, at very low certainty, and noted that six of the ten were funded or published by the makers of the products tested¹⁶. The conflict runs through the literature, not through one paper.

The arrangement that avoids the trade is hydroxyapatite kept alongside fluoride instead of replacing it, and that arrangement has independent evidence behind it. Running for two years in 610 children, a triple-blind randomised trial ended with fewer active enamel lesions in the group given hydroxyapatite plus fluoride than in the group given sodium monofluorophosphate at the same fluoride strength¹⁷. Those are children's primary teeth and a caries outcome, not adult sensitivity, and the trial says nothing about how either paste feels on a cold morning. Unlike fluoride-free hydroxyapatite pastes, S3 does not ask you to give up decay protection. The fluoride it keeps is full adult strength, 1450 ppm as sodium monofluorophosphate.

What do the alternatives cost, once every tube is priced at the same size?

Between seventy-five pence and thirty-seven pounds for the volume of a standard tube, and the price does not track the evidence. The cheapest row on the table is a supermarket-priced own label carrying potassium nitrate and the same 1450 ppm sodium fluoride as branded potassium pastes selling for five or six times as much. The cheapest stannous fluoride option recorded is £2.50 for 75 ml, and stannous fluoride holds the sole high-confidence two-week row in the 2026 network meta-analysis, which is neither S3's chemistry nor the market leader's flagship¹. At the other end, a 20 ml serum works out at £37.46 for the same volume as a standard tube, and a hydroxyapatite paste priced at £25 for a first order is not on the table at all because its size is not on the row.

Before anyone reads that spread as a value ranking, the gap in the literature has to be stated. A PubMed search run for this page in September 2026 for cost-effectiveness or economic evaluation in dentine hypersensitivity returned three records, and not one of them is about a desensitising toothpaste: a protocol for silver fluoride in aged care, an umbrella review of lasers, and a review of fluoride in root caries. Nobody has published a cost-effectiveness comparison of these toothpastes. The price column is a price column.

A second search, for dose or concentration or dose-response in desensitising dentifrices, returned a dozen records and no clinical dose-response trial for any of the five actives. That matters at the shelf, because a declared percentage reads like a strength rating and is not one: nobody has published a head-to-head of two concentrations of the same desensitising active in a toothpaste in people. Where S3 states 5% potassium nitrate it is stating the concentration the published trials used, at a clinically proven 5% dose, and not a concentration shown to beat another.

Which alternatives cover both mechanisms, and where does S3 sit on this shelf?

Two rows on the table carry a nerve active and an occluder in the same tube, and both keep fluoride. Spotlight Sensitivity + Rebuilding Pro pairs potassium citrate with hydroxyapatite and sodium fluoride; S3 pairs potassium nitrate with nano-hydroxyapatite and biomimetic hydroxyapatite and sodium monofluorophosphate. Everything else on the shelf asks you to pick a side.

The argument for pairing is mechanical before it is statistical. Hydroxyapatite occludes; potassium desensitises; a formula built for sensitivity needs both. The pooled support for the pairing is one node in one network: potassium combined with hydroxyapatite showed standardised mean differences of 2.47 on the tactile stimulus and 2.44 on air against a fluoride paste in the 2020 review, among the largest estimates there, and it rests on a small number of contributing trials³. The newest network does not carry the combination as a node at all¹, and no trial has tested S3's own three-active formula as a finished product.

What has been tested is the two actives against each other. In an unblinded four-week randomised trial in 39 adults, a hydroxyapatite toothpaste relieved air-blast sensitivity as well as a potassium nitrate toothpaste, both significantly from baseline, with no difference found between them¹⁸. And in an eight-week double-blind trial of 85 adults, industry-funded by the company that made the test products, 10% and 15% nano-hydroxyapatite pastes, with and without added potassium nitrate, were as effective as calcium sodium phosphosilicate¹⁹. The ingredients in S3 rest on 120+ published studies of that kind, which is a statement about the ingredients and not about the tube.

Where S3 is not the answer: if you have never tried an occluder and want the cheapest way to test one, this shelf holds cheaper answers than a £19.99 tube, and the table above names them. S3 is for the reader whose current sensitivity toothpaste worked at first and then stopped, for the reader who wants hydroxyapatite without dropping fluoride, and for the reader who would rather repair the surface than only calm the nerve.

What does "dentist recommended" mean on a sensitivity toothpaste?

It means a survey, and the brand that uses it publishes the basis in a footnote. On its own United Kingdom FAQ page the market leader states that it "is the No.1 dentist recommended toothpaste brand for sensitive teeth", footnoted to a market-research firm with a year and an address to write to for verification; the survey itself is not published on the page. That is the brand's statement about itself, quoted as it stands, and this page passes no verdict on it.

Two things are worth knowing beside it. The first is that the Oral Health Foundation, whose sensitive-teeth guidance is the one most often quoted back at British readers, names potassium citrate, potassium nitrate and stannous fluoride as the ingredients to look for, says these pastes work by blocking the tiny channels in dentine, and says the effect has to be maintained by continued use²⁰. That page also discloses, at its foot, that it is supported by an educational grant from a toothbrush and toothpaste maker, which is the kind of thing a reader should be told rather than left to find²⁰. The second is that a recommendation and an ownership stake are different kinds of fact. S3 is owned by more than 20 UK dentists, who put their own money into it. That is not evidence the paste works, and it is not offered as any; it is a fact about the company, and the reader can weigh it against a survey.

How do you choose, and when is a dentist the answer instead?

Name the active you have had, pick a tube with a different one, keep the fluoride, and give it eight weeks before deciding. If your old tube was potassium, the cheapest honest experiment on this shelf is a stannous fluoride paste at £2.50 for 75 ml. If your old tube was a glass or a stannous paste, a potassium nitrate own label at seventy-five pence per 75 ml tells you within a couple of months whether the nerve half was the missing half, and costs less than a coffee to find out. If you want both halves in one tube, the table has two rows and one of them is ours. If you want hydroxyapatite and will not drop fluoride, three competitors and S3 qualify. The page on how long to give a new tube sets out the eight-week test properly; this one only tells you which tube to run it on.

None of that applies once the pain has changed character. One tooth rather than several, an onset that was sudden, pain at the severe end, or weeks of sensitivity that will not settle: the Oral Health Foundation treats each as a reason to book an appointment rather than buy a tube, since each can point to decay, a crack, gum disease or infection²⁰. For toothache the NHS clock is shorter still: anything past forty-eight hours belongs to a dentist, and swelling near the eye or in the neck is an emergency²¹. A toothpaste is not a diagnosis, and no active in the table above changes that. The Journal covers the same ground from the ingredient side in its guide to choosing a toothpaste for sensitive teeth, and its page on how sensitive toothpastes work and why yours might not be working takes up what happens when a mechanism reaches its ceiling.

Frequently asked questions

Is there a cheaper alternative with the same active as my Sensodyne?

For the potassium and stannous variants, yes, and by a wide margin. A pharmacy own label at £1.00 for 100 ml carries potassium nitrate and the same 1450 ppm sodium fluoride as branded potassium pastes at £5.00 and above, and the cheapest recorded stannous fluoride paste is £2.50 for 75 ml. The bioactive-glass variants are the exception: the glass is a proprietary ingredient and no own label recorded in the review carries it.

Should I avoid fluoride-free hydroxyapatite pastes?

Not on safety grounds, and this page will not pretend the evidence is settled. What a fluoride-free paste asks you to give up is decay protection, and the pooled randomised evidence in people under 25 found no detectable difference in caries outcomes between hydroxyapatite and fluoride toothpastes, while an independent review of nano-hydroxyapatite for caries found no conclusive evidence at very low certainty¹⁴¹⁶. If you would rather not take that bet, pastes that carry hydroxyapatite and fluoride together exist, and the table names them.

Which alternative works fastest?

None of them inside a week, on the published evidence. The 2019 systematic review of 74 randomised trials found only in-office treatments reaching significance within seven days; stannous fluoride and hydroxyapatite reached it in the medium term and potassium nitrate in the long term¹³. An industry-funded examiner-blind trial of 215 adults found a bioactive-glass paste ahead of a fluoride paste from day three and still widening its lead at day 56, which is the earliest well-measured separation on this shelf¹¹. Judge any tube at the eight-week point the trial protocols use, not at the weekend.

Is there a cheaper alternative to S3 with the same three actives?

On the ingredient lists recorded in the category review, the three actives appear together in S3's tube and nowhere else in the scan. Spotlight Sensitivity + Rebuilding Pro comes closest at £16.00 for 100 ml, with potassium citrate in place of the nitrate, and nobody has compared the two salts head to head in a trial. The honest starting point for a reader who wants to spend as little as possible is still the own-label potassium nitrate paste at seventy-five pence per 75 ml: it is a tenth of the price, it is the same nerve active as three of the market leader's variants, and if it works you have saved yourself a great deal of money.

Do dentists recommend one class over another?

The most recent pooled review that graded its own confidence put stannous fluoride and arginine forward as first-line self-care, and said the choice between them should rest on preference, tolerability and availability rather than an expectation that one outdoes another¹. The Oral Health Foundation's guidance names potassium citrate, potassium nitrate and stannous fluoride, and stresses continued use over the choice of active²⁰. Neither is a survey of what dentists say at the chairside, and neither ranks a brand.